Surrozen Inc (SRZN) - Total Assets
Based on the latest financial reports, Surrozen Inc (SRZN) holds total assets worth $94.05 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Surrozen Inc's book value for net asset value and shareholders' equity analysis.
Surrozen Inc - Total Assets Trend (2019–2024)
This chart illustrates how Surrozen Inc's total assets have evolved over time, based on quarterly financial data.
Surrozen Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Surrozen Inc's total assets of $94.05 Million consist of 80.3% current assets and 19.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 71.3% |
| Accounts Receivable | $2.54 Million | 5.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Surrozen Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SRZN company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Surrozen Inc's current assets represent 80.3% of total assets in 2024, an increase from 69.2% in 2019.
- Cash Position: Cash and equivalents constituted 71.3% of total assets in 2024, up from 68.5% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 5.2% of total assets.
Surrozen Inc Competitors by Total Assets
Key competitors of Surrozen Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Surrozen Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.15 | 7.40 | 6.90 |
| Quick Ratio | 13.15 | 7.40 | 6.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $79.33 Million | $39.17 Million | $42.95 Million |
Surrozen Inc - Advanced Valuation Insights
This section examines the relationship between Surrozen Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.50 |
| Latest Market Cap to Assets Ratio | 4.03 |
| Asset Growth Rate (YoY) | 5.2% |
| Total Assets | $48.47 Million |
| Market Capitalization | $195.43 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Surrozen Inc's assets at a significant premium (4.03x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Surrozen Inc's assets grew by 5.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Surrozen Inc (2019–2024)
The table below shows the annual total assets of Surrozen Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $48.47 Million | +5.18% |
| 2023-12-31 | $46.08 Million | -48.48% |
| 2022-12-31 | $89.44 Million | -34.80% |
| 2021-12-31 | $137.17 Million | +121.03% |
| 2020-12-31 | $62.06 Million | +46.08% |
| 2019-12-31 | $42.48 Million | -- |
About Surrozen Inc
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which co… Read more